# Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists

**Authors:** Mateusz Małkowski, Agnieszka Almgren-Rachtan, Magdalena Olszanecka-Glinianowicz, Jerzy Chudek, Piotr Chłosta

PMC · DOI: 10.3390/ph17010116 · 2024-01-16

## TL;DR

This study examines how often patients with overactive bladder stick to solifenacin therapy and why they stop or don't use it regularly.

## Contribution

The study identifies predictors of solifenacin discontinuation and non-regular use in real-world clinical settings.

## Key findings

- 81.6% of patients continued solifenacin therapy, and 88.6% used it regularly over two visits.
- Persistence was predicted by age ≥75, male sex, rural/small-city dwelling, and ≥10 mg prescriptions.
- Dissatisfaction with therapy was the most common reason for discontinuation.

## Abstract

Solifenacin, a selective muscarinic receptor antagonist, is one of the best-tolerated and most effective medicines that relieve storage symptoms in patients with an overactive bladder (OAB). However, the persistence of solifenacin in daily clinical practice remains far below that reported in clinical trials. This study aimed to analyze the adherence of patients to the therapy and the reasons for solifenacin discontinuation and non-regular use in OAB patients managed by urologists. Data concerning non-compliance and the discontinuation of solifenacin, along with the reasons, were collected during two consecutive visits for 64,049 OAB outpatients. Over the two visits, 81.6% of the patients continued therapy, and 88.6% were taking solifenacin regularly. An age ≥ 75 yrs., the male sex, a rural or small-city dwelling, and a prescription of ≥10 mg predicted therapy continuation. The female sex, a higher education, a short or long duration of an OAB, and a non-idiopathic OAB predicted regular use. The persistence of nycturia and urinary incontinence during therapy predicted both discontinuation and non-regular use. Dissatisfaction with therapy was the most frequent reason for discontinuation. In conclusion, an initial prescription of solifenacin at a low dose reduces the chance of OAB symptom improvement and results in more frequent discontinuation. A high rate of discontinuation related to dissatisfaction suggests unrealistic expectations for OAB patients and insufficient education by urologists.

## Linked entities

- **Chemicals:** solifenacin (PubChem CID 154059)
- **Diseases:** overactive bladder (MONDO:0006624)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382), dry mouth (MESH:D014987), constipation (MESH:D003248), OAB (MESH:D053201), blurred vision (MESH:D014786), Dementia (MESH:D003704), urge incontinence (MESH:D053202), myasthenia gravis (MESH:D009157), neurological diseases (MESH:D020271), Neurological disorders (MESH:D009461), bladder obstruction (MESH:D001748), incontinence (MESH:D014549), anxiety (MESH:D001007), drug (MESH:D000081015), depression (MESH:D003866), urinary frequency (MESH:D006316), urinary urgency (MESH:D014548), gastrointestinal adverse events (MESH:D002318), autonomic neuropathy (MESH:D009422), nycturia (MESH:D053158), injury to people or property (MESH:C000719191)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC10820369